Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04182620 · ClinicalTrials.gov registry record · NA

Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

A NA study, sponsored by Vivek Reddy.

Completed
Registry status
NA
Development phase
160
Enrollment target

NCT04182620 is a NA study that has completed, run by Vivek Reddy. The registered enrollment target is 160 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04182620, a NA study, has completed, sponsored by Vivek Reddy.

COMPLETED
Registry status
NA
Development phase
160 participants
Enrollment target

Study Summary

The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation (RDN) in the prevention of Atrial Fibrillation (AF) recurrence in patients scheduled for an AF ablation procedure. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).

Interventions

  • DEVICE Catheter ablation
  • DEVICE renal denervation

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2020-07-08
Est. Completion 2025-02-26
Phase NA

Sponsor

Vivek Reddy

20 total trials

What the Registry Record Tells You About NCT04182620

The ClinicalTrials.gov registry entry for NCT04182620 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vivek Reddy, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Catheter ablation is the first listed.

NCT04182620 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04182620 about?

NCT04182620 is a clinical study titled "Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation". The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation (RDN) in the prevention of Atrial Fibrillation (AF) recurrence in patients scheduled for an AF ablation procedure. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sy...

What is the current status of trial NCT04182620?

This trial is currently completed. It is a NA study. The enrollment target is 160 participants. The study started on 2020-07-08. Estimated completion is 2025-02-26.

What interventions are being tested in trial NCT04182620?

The interventions under investigation include: Catheter ablation (DEVICE), renal denervation (DEVICE).

Who is sponsoring clinical trial NCT04182620?

This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.